Description
Rucaparib (AG014699) tartrate is an orally active inhibitor of PARP proteins (PARP-1, PARP-2, and PARP-3) and acts on PARP-1 (Ki: 1.4 nM). It is also a hexose hexaphosphate dehydrogenase (H6PD) inhibitor and has potential for use in the study of destructive resistant prostate cancer (CRPC).